Klebsiella pneumoniae: Development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages 61-66

  Rodriguez Avial C ^a   Rodriguez Avial I ^b   Merino, P ^b   Picazo, J J ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Emergence; Integron; Resistance; Tigecycline; VIM 1

Indexed keywords

CEFAZOLIN; CIPROFLOXACIN; EDETIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; METALLO BETA LACTAMASE; TIGECYCLINE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL GENE; BACTERIUM ISOLATE; BLOOD CULTURE; CASE REPORT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MAPPING; GENETIC IDENTIFICATION; HUMAN; INTEGRON; KIDNEY GRAFT; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RECURRENT DISEASE; RENAL GRAFT DYSFUNCTION; SEQUENCE ANALYSIS; TREATMENT CONTRAINDICATION; URINALYSIS; UROSEPSIS;

KLEBSIELLA PNEUMONIAE;

EID: 83655192053     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03482.x     Document Type: Article

References (31)

1. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 440-458.
2. Walsh TR, Toleman MA, Poirel L et al. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-325.
3. Deshpande LM, Jones RN, Fritsche TR et al. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb Drug Resist 2006; 12: 223-230.
4. Pournaras S, Ikonomidis A, Tzouvelekis LS et al. VIM-12, a novel plasmid-mediated metallo-beta-lactamase from Klebsiella pneumoniae that resembles a VIM-1/VIM-2 hybrid. Antimicrob Agents Chemother 2005; 49: 5153-5156.
5. Giakkoupi P, Xanthaki A, Kanelopoulou M et al. VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003; 41: 3893-3896.
6. Aschbacher R, Doumith M, Livermore DM et al. Linkage of acquired quinolone resistance (qnrS1) and metallo-beta-lactamase (blaVIM-1) genes in multiple species of Enterobacteriaceae from Bolzano, Italy. J Antimicrob Chemother 2008; 61: 515-523.
7. Weile J, Ohler S, Schonthal S et al. A VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany. Int J Antimicrob Agents 2009; 33: 389-391.
8. Tortola MT, Lavilla S, Miro E et al. First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 2005; 49: 3492-3494.
9. Tato M, Coque TM, Ruiz-Garbajosa P et al. Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-beta-lactamase in Spain: toward endemicity? Clin Infect Dis 2007; 45: 1171-1178.
10. Psichogiou M, Tassios PT, Avlamis A et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 2008; 61: 59-63.
11. Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J Antimicrob Chemother 2006; 57: 142-145.
12. Ktari S, Arlet G, Mnif B et al. Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-beta-lactamase, CTX-M-15 extended-spectrum beta-lactamase, and CMY-4 AmpC beta-lactamase in a Tunisian university hospital. Antimicrob Agents Chemother 2006; 50: 4198-4201.
13. Galani I, Rekatsina PD, Hatzaki D et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 2008; 61: 548-553.
14. Picao RC, Andrade SS, Nicoletti AG et al. Metallo-beta-lactamase detection: comparative evaluation of double-disk synergy versus combined disk tests for IMP-, GIM-, SIM-, SPM-, or VIM-producing isolates. J Clin Microbiol 2008; 46: 2028-2037.
15. Castanheira M, Sader H, Deshpande L et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and Metallo-beta-lactamase-producing Enterobacteriaceae. report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 2008; 52: 570-573.
16. Conejo MC, Hernandez JR, Pascual A. Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases. Diagn Microbiol Infect Dis 2008; 61: 343-345.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational Supplement. CLSI Document M100-S19. Wayne, PA: CLSI, 2009.
18. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8: 321-331.
19. Coque TM, Oliver A, Perez-Diaz JC et al. Genes encoding TEM-4, SHV-2, and CTX-M-10 extended-spectrum beta-lactamases are carried by multiple Klebsiella pneumoniae clones in a single hospital (Madrid, 1989 to 2000). Antimicrob Agents Chemother 2002; 46: 500-510.
20. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed- field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233-2239.
21. Gulmez D, Woodford N, Palepou MF et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008; 31: 523-526.
22. Hong T, Smith Moland E, Abdalhamid B et al. Escherichia coli: developement of carbapenem resistance during therapy. Clin Infect Dis 2005; 40: 84-86.
23. Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates. J Clin Microbiol 2005; 43: 494-496.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010.
25. Cobo J, Morosini MI, Pintado V et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 60: 319-322.
26. Daly MW, Riddle DJ, Ledeboer NA et al. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 2007; 27: 1052-1057.
27. Anthony KB, Fishman NO, Linkin DR et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567-570.
28. Kelesidis T, Karageorgopoulos DE, Kelesidis I et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008; 62: 895-904.
29. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 2007; 13: 1-6.
30. Rasheed JK, Jay C, Metchock B et al. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41: 647-653.
31. Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007; 27: 445-461.